The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …

Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …

Gastroesophageal cancer dynamics and drivers of clinical responses with immune
checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual …

The last decade has seen rapid progress in the use of genomic tests, including gene panels,
whole‐exome sequencing, and whole‐genome sequencing, in research and clinical cancer …

The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …

Colorectal cancer (CRC) is one of the most frequent cancers in incidence and mortality.
Despite advances in cancer biology, molecular genetics, and targeted treatments, CRC …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …